Shire PLC  

(Public, LON:SHP)   Watch this stock  
Find more results for SHP
4,589.09
+34.59 (0.76%)
Dec 2 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 4,510.00 - 4,625.50
52 week 2,707.19 - 5,377.00
Open 4,540.00
Vol / Avg. 2.78M/2.94M
Mkt cap 41.18B*
P/E 65.23
Div/yield 3.51*
EPS 0.70*
Shares 903.50M
Beta     -
Inst. own     -
*GBP
Feb 13, 2017
Full Year 2016 Shire PLC Earnings Release (Estimated) Add to calendar
Nov 10, 2016
Shire PLC Investor Day
Nov 1, 2016
Q3 2016 Shire PLC Earnings Call
Nov 1, 2016
Q3 2016 Shire PLC Earnings Release
Sep 28, 2016
Shire PLC at Leerink Partners Rare Disease & IO Roundtable Series - Webcast
Sep 16, 2016
Shire PLC at Bank of America Merrill Lynch Healthcare Conference
Sep 12, 2016
Shire PLC at Morgan Stanley Global Healthcare Conference
Sep 7, 2016
Shire PLC at Wells Fargo Securities Healthcare Conference
  

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -10.65% 20.88%
Operating margin -11.76% 22.12%
EBITD margin - 44.15%
Return on average assets -2.10% 8.86%
Return on average equity -4.96% 14.47%
Employees 5,548 -
CDP Score - 91 B

Address

Hampshire Intl Business Park, Chineham
BASINGSTOKE, RG24 8EP
United Kingdom - Map
+44-1256-894000 (Phone)
+44-1256-894708 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. The Company's products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSEVUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), LIALDA (mesalamine)/MEZAVANT(mesalazine), PENTASA (mesalamine), REPLAGAL (agalsidase alfa), ELAPRASE (idursulfase), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), FOSRENOL (lanthanum carbonate), KALBITOR, CINRYZE C1 esterase inhibitor (human), GATTEX/REVESTIVE, BUMINATE 25% Albumin (Human), BUMINATE 5% Albumin (Human), GLASSIA Alpha1-Proteinase Inhibitor (Human) and ONCASPAR pegaspargase.

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 58
Jeffrey Poulton Chief Financial Officer, Executive Director
Age: 48
Ginger Gregory Chief Human Resource Officer
William Mordan General Counsel, Company Secretary
Phil J. Vickers Head of Research and Development
Age: 56
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Age: 57
Olivier Bohuon Non-Executive Director
Age: 57
Gail D. Fosler Non-Executive Director
Age: 68
Sara Mathew Non-Executive Director
Age: 61
Albert P. L. Stroucken Non-Executive Director
Age: 68